SEC’s Ceresney: Common FCPA Violations in Pharma Industry
Image: From remarks last week at a conference in Washington D.C., SEC Director of Enforcement Andrew Ceresney highlighted three types of Foreign Corrupt Practices Act misconduct that most often arise in the pharmaceutical industry: pay-to-prescribe, formulary drugs, and charitable contributions. More of Ceresney’s observations are inside.
THIS IS MEMBERS-ONLY CONTENT
You are not logged in and do not have access to members-only content.
If you are already a registered user or a member, SIGN IN now.
Related articles
-
Article
Mitigating FCPA Risks in Pharma, Med Device Sectors
Image: SEC Enforcement Director Andrew Ceresney recently dropped new hints on FCPA risks for pharma and medical devices, plus suggestions on how to avoid those risks. “Our FCPA focus obviously covers many industries,” he said. “But the pharma industry is one on which we have been particularly focused in recent ...
-
PremiumGlencore compliance monitorships ended early by DOJ
The U.S. Department of Justice ended two compliance monitorships on Glencore International more than a year early, monitorships imposed in 2022 after the company was convicted of paying bribes and manipulating commodities markets.
-
PremiumTrump family buys into crypto as regulators consider soft touch on the industry
Any doubts that the new administration will take a light touch to upcoming cryptocurrency regulation vanished with President Donald Trump’s launch of his own stablecoin and his family’s growing investments in crypto businesses.